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expressed in E. coli and tested for binding to TIMP-3 by both plate-
and bead-based binding assays. Sequences that bound TIMP-3
were tested for interference with TIMP-3’s inhibition of MMP-13,
using a ﬂuorescence-quench substrate, and for promotion of TIMP-
3 accumulation in HTB-94 cell cultures. TIMP-3 in the media was
assayed by western blot and ELISA. Internalization of exogenous
TIMP-3 was examined by confocal microscopy with A549 cells:
cells were incubated typically with 1 ug/ml TIMP-3 for 30 minutes
at 4 degrees, with or without various pre-treatments, then washed,
ﬁxed and stained with a ﬂuorescently labeled anti-TIMP-3 antibody,
or washed and then incubated further at 4 or 37 degrees before
ﬁxation and staining.
Results: Multiple ecto-domain LRP-1 sequences bound TIMP-3
with submicromolar afﬁnity, including Cluster II (which contains
8 ligand binding domains) and parts of Cluster IV. The Cluster
IV sequences substantially impaired TIMP-3’s inhibition of MMP-
13, but Cluster II had a minimal effect on this inhibitory activity.
Moreover, Cluster II caused an accumulation of TIMP-3 in HTB-
94 cell cultures comparable to that seen in the presence of
heparin, which is believed to prevent TIMP-3 from binding to the
cell surface. Cells that lack LRP-1 were found to accumulate
TIMP-3 in the medium to a greater extent than wild-type cells.
The confocal microscopic analysis showed that TIMP-3 binds
to the cell surface by a heparin-competible mechanism, rapidly
disappears when the cells are incubated at 37 degrees but not at
4 degrees, and accumulates inside the cells if they are pre-treated
with chloroquine to prevent lysosomal degradation.
Conclusions: TIMP-3 can bind directly to the LRP-1 scavenger
receptor. Some TIMP-3-binding fragments of the receptor reduce
the inhibitor’s activity against metalloproteases, but others do not,
and one of these causes an accumulation of TIMP-3 in tissue
culture medium. LRP-1 is required for normal clearance of TIMP-
3, which entails binding to the cell surface, internalization, and
degradation by lysosomes.
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Purpose: Background: Several Hyaluronic acids (HA) are cur-
rently available for the management of KOA. Some assertions
have been made regarding a potential better efﬁcacy of the high-
est MW products. However, results of existing published trials are
controversial.
Objectives: To compare the efﬁcacy and safety of a "medium" MW
(F60027, Structovial) and a "high" MW (Hylan G-F 20, Synvisc)
HA on function and pain in KOA.
Methods: We conducted a multicentre, double-blind (injector and
clinical assessor blinded to each other), active controlled, parallel-
group study, according to a non-inferiority design. Patients aged 50
- 75 years with symptomatic KOA (ACR criteria) were randomized
to receive 3 intra-articular injections at weekly intervals of either
F60027 or Hylan G-F20. Inclusion criteria were: global pain in
the target knee > or = 40 mm on a 100-mm visual analog scale
(VAS), Lequesne’s Algofunctional Index (LFI) score > 7 (range: 0-
24) and radiological Kellgren-Lawrence grade 2 or 3. The primary
outcome was the LFI score change between baseline and week
24. Secondary assessments were pain VAS, quality of life (SF-12),
patient’s and physician’s global assessments on VAS at baseline,
weeks 1, 2, 6, 12, 18 and 24. Safety was assessed by recording
any adverse events. A non-inferiority test was assessed: 95%
conﬁdence interval (CI) of the difference F60027 - Hylan G-F20
on change of LFI score. Pre-determined non inferiority limit was
settled as the lower limit of the 95% CI above -1.25.
Results: 279 patients were randomized: 276 analyzed in the full
analysis dataset (FAS), 236 in the per protocol (PP) analysis. No
difference between groups at entry regarding demographics and
disease characteristics. The main efﬁcacy analysis (PP) showed
no difference between F60027 and Hylan G-F20 on mean vari-
ations of the LFI score over 24 weeks which varied by -4.67
(0.27) in F60027 group and -4.54 (0.28) in Hylan G-F20 group ;
difference = 0.132 [95%CI: -0.598, 0.861]. The -0.598 lower limit
of the CI was above the pre-trial selected non inferiority margin
of -1.25, which clearly demonstrated the non inferiority of F60027
compared to Hylan G-F20. The analysis on the FAS gave similar
results. Analyses of the secondary efﬁcacy endpoints on both
PP/FAS populations showed the same trends for each treatment
with improvements of clinical relevance of all outcomes at week
24. Improvement on function and pain translated into an improve-
ment on the physical component of SF12. Maximum improvement
was achieved at week 6 and maintained up to week 24. Changes
of the LFI score between baseline and week 24 were -5.73 in
the F60027 group and -5.57 in the Hylan G-F20 group giving an
intra-group effect size of 1.48 and 1.44 respectively.
Both treatments were well tolerated. Local reactions such as pain
at injection site were reported in 3.6% of patients in each group.
Conclusions: F60027 and Hylan G-F20 were equally effective in
reducing functional impairment and pain over a 6 month period of
time in KOA patients, without any safety concerns.
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Purpose: Intra-articular hyaluronic acid (HA) injections of the knee
have been established to both lubricate and replenish the surface
cartilage of the knee joint. This is accomplished when HA stim-
ulates chondrocytes to produce a substance that is similar to
cartilage. The cationic articular brace (CAB) functions by stimulat-
ing chondrocytes at a particular electromagnetic frequency which
can lead to the production of more cartilage. Over the course of
two years approximately 30% of patients treated with this brace
can demonstrate an increase in joint space by MRI associated
with functional and symptomatic improvement.
In this case presentation of advanced osteoarthritis of the knee,
serial intra-articular HA injections when tried singularly provided
only minimal pain relief. The patient’s cardiac status eliminated
surgery as a therapeutic option. Symptomatically the patient’s
pain severely impaired his ability to ambulate. It was only when
the concomitant combination of intra-articular HA injections and
CAB therapy was used for his knee that the patient’s pain was
sufﬁciently relieved such that he was able to increase his ability to
ambulate.
Methods: For approximately a 1 year period the patient recieved
2 cycles of intra-articular HA injections to both knees. The symp-
tomatic and functional beneﬁt was noted. Then over a 2 year
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interval each knee received a series of 5 weekly intra-articular
hyaluronic acid injections every six months. During that same in-
terval the patient wore CAB on each knee when he went to bed
- ie. approximately 7 hrs. nightly. Again during this period both
symptomatic and functional beneﬁt were noted. After this period,
commercial difﬁculty was encountered in obtaining replacement
electrodes and appropriate gel and the brace could no longer be
worn. Again symptomatic and functional changes were noted.
Results: At the onset, functionally the patient was barely able to
walk from my ofﬁce to his car in the parking lot (ie. approx. 30
yds.) with a cane. Pain was 10/10. Using only serial intra - articular
HA injections resulted in only minimal pain reduction - ie. 8/10.
His functional ability to walk remained at approx. 30 yds. However
after adopting concomitant combination therapy of both modalities
the patient was aware of a progressive gradual reduction in his
bilateral knee pain after 3 months. After 9 months his pain was
0/10 and he was able to walk >60 yds. Of interest the functional
and symptomatic beneﬁt was gradually diminished once he no
longer had access to the necessary replacement electrodes and
gel ie. 8/10. His ability to walk was decreased to approx. 60 yds.
He continues with intra-articular HA injections to both knees every
six months - both symptomatic and functional parameters have
not signiﬁcantly changed.
Conclusions: Although this is a single case, it has clinical im-
portance. That the CAB was therapeutically valid is underlined by
the fact that it was FDA approved for both osteoarthritis of the
knee and rheumatoid arthritis of the hand. Given its demonstrated
clinical efﬁcacy, it is known that prototypes were being developed
for other joints in the body as well as an improved version of the
brace itself. The clinical signiﬁcance of concomitant combination
HA injection and CAB therapy needs to be validated. In the past it
has been possible to grow a patient’s cartilage outside the joint -
ie. in a Petri dish. The inevitable difﬁculty however was to get car-
tilage to effectively attach to subchondral bone. This process may
offer a solution to this dilemma and merits ulterior independent
investigation.
Therapy – Non-Pharmacologic
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Purpose: To evaluate the expediency of an inﬂammation-sensitive
and disease-regulated cyclooxygenase-2 (Cox-2) promoter to ex-
ploit therapeutic potential of canine interleukin (IL)-4 gene in vitro.
Methods: Chondrocytes from canine knee cartilage were “condi-
tioned” by ex vivo gene transfer using IL-4 as a therapeutic trans-
gene downstream of Cox-2 promoter (devoid of viral sequence).
Chondrocyte/scaffold constructs were engineered using two types
of biomaterials. The cells were either encapsulated in alginate mi-
crospheres or trapped in transplants. The latter were generated by
employing a rat-tail collagen type I cartilage regeneration system.
Recombinant proinﬂammatory canine cytokines IL-1β and tumour
necrosis factor (TNF)α were used to simulate inﬂammatory arthritis
in chondrocytes within these scaffolds. Multiple inﬂammation and
cartilage markers were monitored to evaluate the antiinﬂammatory
and regulatory characteristics of IL-4.
Results: It was shown that in the presence of proinﬂammatory cy-
tokines, IL-1β and TNFα, the Cox-2 promoter was “switched on” to
drive the expression of antiinﬂammatory IL-4 gene. The controlled
and ﬁne-tuned expression of IL-4 down-regulated the inﬂamma-
tory cytokines such as IL-1β, IL-6, TNFα and enzyme mediators as
inducible nitric oxide synthase (iNOS), Cox-2 and matrix metallo-
proteinases (MMPs)-3 and -13. Synthesis of two major destructive
mediators namely nitric oxide (NO) and prostaglandin E2 (PGE2)
was also reduced. At the same time, an up-regulated expression of
the insulin-like growth factor (IGF)-1, IL-1 receptor antagonist (IL-
1Ra) and collagen type II was observed. These ﬁndings represent
proof-of-concept of our previous studies in monolayer cultures.
There was virtually no marked difference between the two scaf-
folds in the context of expression pattern of various marker genes.
However, it is tempting to speculate that alginates are easy to use
and can enter in small cartilage defects but could be fragile during
surgery. On the other hand, the collagen scaffold may be useful
to cover larger cartilage lesions. While these results substantiate
our previous ﬁndings, at the same time they potentiate the need
for application of a disease-driven, self-limiting, species-speciﬁc
therapy for osteoarthritis in vivo.
Conclusions: We propose that the application of cytokine therapy
based on ex vivo gene transfer through a non-viral, disease-
regulated promoter combined with autologous chondrocyte trans-
plantation could potentially serve as a useful tissue engineering
tool towards devising therapeutic strategies for the treatment of
osteoarthritis.
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Purpose: Among the rheumatic diseases, osteoarthritis (OA) is
the most frequent. Joint lavage is just another way to treat it.
It is useful in degenerative and inﬂammatory diseases. It has
been used either in knee and shoulder joints, and it is getting
more used as an effectiveness treatment in hip joint. The aim
of the hip joint lavage (HJL) is to evacuate ﬁbrin remains and
microcrystal, dissolve inﬂammatory molecules, and, also, induce
vasoconstriction through cooling. It is done in a speciﬁc box in
our outpatient clinics care ofﬁce. The objective of this study is to
evaluate the efﬁcacy and the safety of the HJL after one and three
months, in patients affected of OA of the hip.
Methods: We recruited 22 patients (22 hips), mean age 70 years-
old, with painful hip OA grades II and III (Kellgren-Lawrence Index),
from our outpatient clinics, in Hospital de la Santa Creu I Sant Pau,
in Barcelona. We used the Golding technique for the punction, to
access the joint, with a 1.1 mm diameter trochar, and using local
anesthesy with Mepivacaine 2%. We also performed a 500 cc
physiological serums 0.09% perfusion (at 18-20°C) by positive
pressure. We also performed a second punction to allow the way
out of the serum. The whole intervention took 30 minutes. The
efﬁcacy was evaluated by WOMAC, LEQUESNE and Pain-VAS
indexes. Statistical analysis was completed by SPSS program.
Results: HJL showed efﬁcacy diminishing Pain-VAS mean from
basal register to 3-months one (7.33 to 5.33), which represented
a signiﬁcant difference (p<0,001). WOMAC pain domain improved
at 3 months, without signiﬁcant differences, though. The other
parameters evaluated are shown separately in the following ta-
ble, with signiﬁcant differences between basal and later registers
(p=NS).
There were no serious adverse events. Two mild complications
were seen: local pain during the intervention in one patient, and
vagal syndrome in another one. All of them were recovered and
we did not need to stop the intervention.
